[go: up one dir, main page]

WO2008081829A1 - 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ - Google Patents

難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ Download PDF

Info

Publication number
WO2008081829A1
WO2008081829A1 PCT/JP2007/074998 JP2007074998W WO2008081829A1 WO 2008081829 A1 WO2008081829 A1 WO 2008081829A1 JP 2007074998 W JP2007074998 W JP 2007074998W WO 2008081829 A1 WO2008081829 A1 WO 2008081829A1
Authority
WO
WIPO (PCT)
Prior art keywords
poorly water
soluble drug
aminoalkylmethacrylate copolymer
maintaining solubility
aminoalkylmethacrylate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2007/074998
Other languages
English (en)
French (fr)
Inventor
Takatsune Yoshida
Keiichi Yoshihara
Hiroyuki Umejima
Ippei Kurimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Priority to EP07860227A priority Critical patent/EP2127677A4/en
Priority to JP2008552132A priority patent/JPWO2008081829A1/ja
Priority to CA002673959A priority patent/CA2673959A1/en
Publication of WO2008081829A1 publication Critical patent/WO2008081829A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

　アミノアルキルメタアクリレートコポリマーＥと酸性物質を均一に配合したアミノアルキルメタアクリレートコポリマーＥ及び難水溶性薬物を含む難水溶性薬物の溶解性を少なくとも３０分間維持する医薬組成物を開示する。
PCT/JP2007/074998 2006-12-27 2007-12-26 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ Ceased WO2008081829A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP07860227A EP2127677A4 (en) 2006-12-27 2007-12-26 AMINO ALKYL METHACRYLATE COPOLYMER FOR MAINTAINING THE SOLUBILITY OF A HEAVY WATER-SOLUBLE MEDICAMENT
JP2008552132A JPWO2008081829A1 (ja) 2006-12-27 2007-12-26 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ
CA002673959A CA2673959A1 (en) 2006-12-27 2007-12-26 Aminoalkyl methacrylate copolymer e for maintaining solubility of poorly-soluble drug

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87716506P 2006-12-27 2006-12-27
US60/877,165 2006-12-27

Publications (1)

Publication Number Publication Date
WO2008081829A1 true WO2008081829A1 (ja) 2008-07-10

Family

ID=39588511

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/074998 Ceased WO2008081829A1 (ja) 2006-12-27 2007-12-26 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ

Country Status (5)

Country Link
US (1) US20080221047A1 (ja)
EP (1) EP2127677A4 (ja)
JP (1) JPWO2008081829A1 (ja)
CA (1) CA2673959A1 (ja)
WO (1) WO2008081829A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013500279A (ja) * 2009-07-30 2013-01-07 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング アミノ（メタ）アクリレートポリマー又はコポリマーを含有する水性炭酸媒体
JP2017031087A (ja) * 2015-07-31 2017-02-09 東洋精糖株式会社 α−グルコシルルチン含有プテリジン誘導体ナノ粒子の製造方法およびα−グルコシルルチン含有プテリジン誘導体ナノ粒子
WO2017204210A1 (ja) 2016-05-24 2017-11-30 三生医薬株式会社 経口医薬組成物及び該組成物からなる粒子状製剤の製造方法
JP2018024628A (ja) * 2016-08-02 2018-02-15 ニプロ株式会社 トルバプタンを含む非晶質固体分散体およびその製造方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2737400C (en) * 2008-10-07 2016-11-22 Astrazeneca Uk Limited Pharmaceutical formulation 514
CN102293734A (zh) * 2010-06-25 2011-12-28 江苏恒瑞医药股份有限公司 托伐普坦固体分散体及其制备方法
WO2014182710A1 (en) * 2013-05-06 2014-11-13 The Regents Of The University Of Minnesota Sugar containing, amphiphilic copolymers
JP6753312B2 (ja) * 2014-12-26 2020-09-09 ニプロ株式会社 医療用皮膚外用剤

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0374396A (ja) * 1989-08-16 1991-03-28 Mercian Corp 抗菌性組成物
WO1994006414A1 (fr) 1992-09-18 1994-03-31 Yamanouchi Pharmaceutical Co., Ltd. Preparation d'hydrogel a liberation prolongee
WO1995020380A1 (en) 1994-01-31 1995-08-03 Yamanouchi Pharmaceutical Co., Ltd. Intraorally soluble compressed molding and process for producing the same
JP2000095708A (ja) 1998-09-22 2000-04-04 F Hoffmann La Roche Ag 低溶解性化合物の安定な複合体
WO2001078686A1 (en) 2000-04-17 2001-10-25 Yamanouchi Pharmaceutical Co., Ltd. Time-release coated solid compositions for oral administration
WO2002005786A1 (en) 2000-07-17 2002-01-24 Yamanouchi Pharmaceutical Co., Ltd. Pharmaceutical composition improved in peroral absorbability
WO2003059389A1 (en) * 2002-01-16 2003-07-24 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions for improving oral absorption
JP2005500313A (ja) 2001-06-22 2005-01-06 ファイザー・プロダクツ・インク 基材中の低可溶性薬物の固体分散体および溶解度向上性ポリマーを含有する医薬品組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5445830A (en) * 1989-07-25 1995-08-29 Otsuka Pharmaceutical Co., Ltd. Highly absorbable pharmaceutical composition
AU749623B2 (en) * 1998-03-26 2002-06-27 Astellas Pharma Inc. Sustained release preparations
WO2004071510A1 (en) * 2003-02-11 2004-08-26 Cipla Ltd Pharmaceutical composition comprising immunosuppressants for the treatment of dermatophytosis
KR100691608B1 (ko) * 2005-02-21 2007-03-12 (주)나노하이브리드 염기성 고분자가 첨가된 유리 염기형 약물과 층상형 규산염의 하이브리드 및 그의 제조방법

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0374396A (ja) * 1989-08-16 1991-03-28 Mercian Corp 抗菌性組成物
WO1994006414A1 (fr) 1992-09-18 1994-03-31 Yamanouchi Pharmaceutical Co., Ltd. Preparation d'hydrogel a liberation prolongee
WO1995020380A1 (en) 1994-01-31 1995-08-03 Yamanouchi Pharmaceutical Co., Ltd. Intraorally soluble compressed molding and process for producing the same
JP2000095708A (ja) 1998-09-22 2000-04-04 F Hoffmann La Roche Ag 低溶解性化合物の安定な複合体
WO2001078686A1 (en) 2000-04-17 2001-10-25 Yamanouchi Pharmaceutical Co., Ltd. Time-release coated solid compositions for oral administration
WO2002005786A1 (en) 2000-07-17 2002-01-24 Yamanouchi Pharmaceutical Co., Ltd. Pharmaceutical composition improved in peroral absorbability
JP2005500313A (ja) 2001-06-22 2005-01-06 ファイザー・プロダクツ・インク 基材中の低可溶性薬物の固体分散体および溶解度向上性ポリマーを含有する医薬品組成物
WO2003059389A1 (en) * 2002-01-16 2003-07-24 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions for improving oral absorption

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Prograf Chushaeki 5mg", TENPU BUNSHO, October 2006 (2006-10-01), pages 1 - 6, XP008117001 *
KATHRIN NOLLENBERGER ET AL.: "Increasing the solubility of Felodipine by preparing solid dispersions with melt extrusion", DEGUSSA, PHARMA POLYMERS, no. 1240, 2006
See also references of EP2127677A4 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013500279A (ja) * 2009-07-30 2013-01-07 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング アミノ（メタ）アクリレートポリマー又はコポリマーを含有する水性炭酸媒体
JP2017031087A (ja) * 2015-07-31 2017-02-09 東洋精糖株式会社 α−グルコシルルチン含有プテリジン誘導体ナノ粒子の製造方法およびα−グルコシルルチン含有プテリジン誘導体ナノ粒子
WO2017204210A1 (ja) 2016-05-24 2017-11-30 三生医薬株式会社 経口医薬組成物及び該組成物からなる粒子状製剤の製造方法
EP4279137A2 (en) 2016-05-24 2023-11-22 Sunsho Pharmaceutical Co., Ltd. Oral pharmaceutical composition and method for producing particulate formulation comprising composition
JP2018024628A (ja) * 2016-08-02 2018-02-15 ニプロ株式会社 トルバプタンを含む非晶質固体分散体およびその製造方法

Also Published As

Publication number Publication date
JPWO2008081829A1 (ja) 2010-04-30
EP2127677A1 (en) 2009-12-02
EP2127677A4 (en) 2012-05-02
US20080221047A1 (en) 2008-09-11
CA2673959A1 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
WO2008081829A1 (ja) 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ
IL190951A0 (en) Method of acting upon organism by targeted delivery of biologicaly active substances into mitochondria, pharmaceutical composition for carrying out said method, and compound used for the purpose
EP2004172A4 (en) ACTIVE INK PROCESSING, STRUCTURES AND COMPOSITIONS FOR NASOLACRIMAL SYSTEM
WO2007149406A8 (en) Modified coagulation factor ix polypeptides and use thereof for treatment
WO2004082628A3 (en) Improved bioavailability and improved delivery of acidic pharmaceutical drugs
WO2008033351A3 (en) Multimodal abuse resistant and extended release formulations
IL192967A0 (en) Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
IL228017A0 (en) Quinazolinone derivatives donated at position 5 as anti-cancer agents
ZA200807767B (en) Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
UA94942C2 (ru) Фармацевтические композиции с ингибиторами dpp iv
WO2006060547A3 (en) Systems and methods for intra-oral drug delivery
BRPI0710508B8 (pt) composição de pepticorpo terapêutico liofilizado estável, kit para preparar uma composição farmacêutica aquosa, e métodos para fabricar um pepticorpo terapêutico liofilizado e para preparar uma composição de pepticorpo terapêutico reconstituído
WO2009061607A3 (en) Water-immiscible materials as vehicles for drug delivery
WO2009111057A3 (en) Fulvestrant formulations
IL193772A0 (en) 4-oxoquinoline derivatives,methods for the preparation thereof and pharmaceutical compositions containing the same
BRPI0908208A2 (pt) Composto derivado de oxazolidinona, medicamento, composição farmacêutica que o contém e uso desse composto.
WO2008084698A1 (ja) タクロリムス徐放性医薬組成物
WO2008006795A3 (en) Indole compounds
WO2006099514A3 (en) Drug delivery compositions and related methods
WO2005065657A3 (en) Solid compositions of low-solubility drugs and poloxamers
NO20074933L (no) Farmasoytisk sammensetning som innbefatter et indolylmaleimidderivat
WO2007090661A3 (en) Active substance combination comprising azolylcarbinol compounds
IL189270A (en) Repamycins converted to phosphonate and their derivatives, pharmaceutical preparations containing them and their use in the prevention and treatment of bone and joint infections
WO2009068708A3 (es) Composición farmacéutica de liberación sostenida de somatostatina o un análogo suyo
TW200718433A (en) Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07860227

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008552132

Country of ref document: JP

Ref document number: 2673959

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007860227

Country of ref document: EP